1. |
Agarwal A, Kumari N, Trehan A, et al. Outcome of cytomegalovirus retinitis in immunocompromised patients without human immunodeficiency virus treated with intravitreal ganciclovir injection[J]. Graefe's Arch Clin Exp Ophthalmol, 2014, 252(9): 1393-1401. DOI: 10.1007/s00417-014-2587-5.
|
2. |
Young S, Morlet N, Besen G, et al. High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis[J]. Ophthalmology, 1998, 105(8): 1404-1410. DOI: 10.1016/s0161-6420(98)98020-4.
|
3. |
Jeon S, Lee WK. Cytomegalovirus retinitis in a human immunodeficiency virus-negative cohort: long-term management and complications[J]. Ocul Immunol Inflamm, 2015, 23(5): 392-399. DOI: 10.3109/09273948.2014.985385.
|
4. |
Miao H, Tao Y, Jiang YR, et al. Multiple intravitreal injections of ganciclovir for cytomegalovirus retinitis after stem-cell transplantation[J]. Graefe's Arch Clin Exp Ophthalmol, 2013, 251(7): 1829-1833. DOI: 10.1007/s00417-013-2368-6.
|
5. |
Zhang C, Wang YE, Miao H, et al. Efficacy and safety of aqueous interleukin-8-guided treatment in cytomegalovirus retinitis after bone marrow hematopoietic stem cell transplantation[J]. Ocul Immunol Inflamm, 2020, 16: 1-8. DOI: 10.1080/09273948.2020.1823422.
|
6. |
Arevalo JF, Garcia RA, Mendoza AJ. High-dose (5000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela[J]. Eur J Ophthalmol, 2005, 15(5): 610-618. DOI: 10.1177/112067210501500512.
|
7. |
Qian Z, Li H, Tao Y, et al. Initial intravitreal injection of high-dose ganciclovir for cytomegalovirus retinitis in HIV-negative patients[J/OL]. BMC Ophthalmol, 2018, 18(1): 314. DOI: 10.1186/s12886-018-0983-z.
|
8. |
Qian Z, Fan H, Chen X, et al. The predictive value of interleukin-8 in the development of cytomegalovirus retinitis in HIV-negative patients[J/OL]. Ophthalmic Res, 2020, 2019: E1(2021-06-16)[2021-12-01]. https://pubmed.ncbi.nlm.nih.gov/33326958/. DOI: 10.1159/000513791. [published online ahead of print].
|
9. |
Moschos M, Vamvasakis M, Kontogeorgos G, et al. Intravitreal application of ganciclovir in rabbits: ERG and electron-microscopic findings[J]. Ophthalmologica, 1996, 210(4): 215-222. DOI: 10.1159/000310712.
|
10. |
狄宇, 郭立斌, 叶俊杰, 等. 兔眼玻璃体腔注射更昔洛韦的视网膜毒性研究[J]. 中华眼科杂志, 2020, 56(4): 279-285. DOI: 10.3760/cma.j.cn112142-20190506-00254.Di Y, Guo LB, Ye JJ. Retinal toxicity study of intravitreal ganciclovir in albino rabbit[J]. Chin J Ophthalmol, 2020, 56(4): 279-285. DOI: 10.3760/cma.j.cn112142-20190506-00254.
|
11. |
Eng KT, Lam WC, Parker JA, et al. Retinal toxicity of intravitreal ganciclovir in rabbit eyes following vitrectomy and insertion of silicone oil[J]. Can J Ophthalmol, 2004, 39(5): 499-505. DOI: 10.1016/s0008-4182(04)80138-8.
|
12. |
McCulloch DL, Marmor MF, Brigell MG, et al. ISCEV standard for full-field clinical electroretinography (2015 update)[J]. Doc Ophthalmol, 2015, 130(1): 1-12. DOI: 10.1007/s10633-014-9473-7.
|
13. |
Gjörloff K, Andreasson S, Ehinger B. Standardized full-field electroretinography in rabbits[J]. Doc Ophthalmol, 2004, 109(2): 163-168. DOI: 10.1007/s10633-004-3924-5.
|
14. |
Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS[J]. Clin Ophthalmol, 2010, 4: 285-299. DOI: 10.2147/opth.s6700.
|
15. |
Vadlapudi AD, Vadlapatla RK, Mitra AK. Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents[J]. Recent Pat Antiinfect Drug Discov, 2012, 7(1): 8-18. DOI: 10.2174/157489112799829765.
|
16. |
Shapira Y, Mimouni M, Vishnevskia-Dai V. Cytomegalovirus retinitis in HIV-negative patients-associated conditions, clinical presentation, diagnostic methods and treatment strategy[J/OL]. Acta Ophthalmol, 2018, 96(7): e761-767[2018-10-25]. https://pubmed.ncbi.nlm.nih.gov/29068151/. DOI: 10.1111/aos.13553.
|
17. |
Drew WL, Miner R, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals[J]. Clin Diagn Virol, 1993, 1(3): 179-185. DOI: 10.1016/0928-0197(93)90012-t.
|
18. |
Hamprecht K, Eckle T, Prix L, et al. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain[J]. J Infect Dis, 2003, 187(1): 139-143. DOI: 10.1086/346240.
|
19. |
Chemaly RF, Chou S, Einsele H, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials[J]. Clin Infect Dis, 2019, 68(8): 1420-1426. DOI: 10.1093/cid/ciy696.
|
20. |
Qian Z, Chen X, Tao Y, et al. Prognostic factors of cytomegalovirus infection associated retinitis in HIV-negative patients: a retrospective cohort study[J]. Ocul Immunol Inflamm, 2021, 29(1): 154-159. DOI: 10.1080/09273948.2019.1659978.
|
21. |
Hu F, Ma Y, Peng X. Does ganciclovir exert retinal toxicity after multiple continuous intravitreal injections?[J]. BMC Infect Dis, 2021, 21(1): 676. DOI: 10.1186/s12879-021-06365-4.
|
22. |
Berthe P, Baudouin C, Garraffo R, et al. Toxicologic and pharmacokinetic analysis of intravitreal injections of foscarnet, either alone or in combination with ganciclovir[J]. Invest Ophthalmol Vis Sci, 1994, 35(3): 1038-1045.
|
23. |
Del Amo EM, Urtti A. Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data[J]. Exp Eye Res, 2015, 137: 111-124. DOI: 10.1016/j.exer.2015.05.003.
|
24. |
Ahn SJ, Hong HK, Na YM, et al. Use of rabbit eyes in pharmacokinetic studies of intraocular drugs[J/OL]. J Vis Exp, 2016, 113: 53878[2016-07-23]. https://pubmed.ncbi.nlm.nih.gov/27500363/. DOI: 10.3791/53878.
|
25. |
del Amo EM, Vellonen KS, Kidron H, et al. Intravitreal clearance and volume of distribution of compounds in rabbits: in silico prediction and pharmacokinetic simulations for drug development[J]. Eur J Pharm Biopharm, 2015, 95(Pt B): 215-226. DOI: 10.1016/j.ejpb.2015.01.003.
|
26. |
López-Cortés LF, Pastor-Ramos MT, Ruiz-Valderas R, et al. Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits[J]. Invest Ophthalmol Vis Sci, 2001, 42(5): 1024-1028.
|
27. |
Liu JH, Farid H. Twenty-four-hour change in axial length in the rabbit eye[J]. Invest Ophthalmol Vis Sci, 1998, 39(13): 2796-2799.
|
28. |
Gasparin F, Aguiar RG, Ioshimoto GL, et al. Pharmacokinetics, electrophysiological, and morphological effects of the intravitreal injection of mycophenolic acid in rabbits[J]. J Ocul Pharmacol Ther, 2014, 30(6): 502-511. DOI: 10.1089/jop.2013.0236.
|
29. |
Iu LPL, Fan MCY, Lam WC, et al. Repeated intraocular crystallization of ganciclovir in one eye after bilateral intravitreal injections: a case report[J]. BMC Ophthalmol, 2018, 18(1): 36. DOI: 10.1186/s12886-018-0703-8.
|
30. |
Choopong P, Tesavibul N, Rodanant N. Crystallization after intravitreal ganciclovir injection[J]. Clin Ophthalmol, 2010, 4: 709-711. DOI: 10.2147/opth.s10949.
|